ADC Therapeutics SA
ADCT
$3.70
-$0.26-6.57%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.41M | -40.97M | -56.65M | -38.60M | -30.73M |
| Total Depreciation and Amortization | 113.00K | 122.00K | 840.00K | 801.00K | 793.00K |
| Total Amortization of Deferred Charges | 246.00K | 733.00K | 650.00K | 191.00K | -557.00K |
| Total Other Non-Cash Items | -13.49M | 10.09M | 15.72M | 10.79M | -1.39M |
| Change in Net Operating Assets | -11.58M | 392.00K | 15.35M | -29.52M | 10.03M |
| Cash from Operations | -31.12M | -29.63M | -24.09M | -56.33M | -21.85M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | -264.00K | -90.00K |
| Sale of Property, Plant, and Equipment | 659.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 659.00K | 0.00 | 0.00 | -264.00K | -90.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.35M | -- | 94.03M | 271.00K | 43.00K |
| Repurchase of Common Stock | -1.26M | -198.00K | -250.00K | -- | -1.16M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 57.09M | -198.00K | 93.78M | 271.00K | -1.12M |
| Foreign Exchange rate Adjustments | -25.00K | 6.00K | 163.00K | 161.00K | -343.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.60M | -29.82M | 69.86M | -56.17M | -23.41M |